New antibiotics for healthcare-associated pneumonia

Authors

Elizabeth A. Neuner, Barnes-Jewish Hospital
David J. Ritchie, Barnes-Jewish Hospital
Scott T. Micek, Barnes-Jewish Hospital

Document Type

Article

Publication Title

Seminars in Respiratory and Critical Care Medicine

Abstract

Current antibiotics available for the treatment of healthcare-associated pneumonia (HCAP) may result in clinical failure due to resistance development, side effect intolerance, or poor pharmacokinetic-pharmacodynamic profiles. New agents active against common HCAP pathogens are needed. The mechanism of action, spectrum of activity, pharmacokinetics, adverse effects, and clinical efficacy of seven new agents in clinical development or recently approved with either methicillin-resistant Staphylococcus aureus (MRSA) or pseudomonal activity are reviewed. They include doripenem, a new antipseudomonal carbapenem; ceftobiprole and ceftaroline, two anti-MRSA cephalosporins; iclaprim, a selective dihydrofolate reductase antagonist; and three glycopeptides, dalbavancin, telavancin, and oritavancin. Copyright © 2009 by Thieme Medical Publishers, Inc.

First Page

92

Last Page

101

DOI

10.1055/s-0028-1119813

Publication Date

2-1-2009

Recommended Citation

Neuner, Elizabeth A.; Ritchie, David J.; and Micek, Scott T., "New antibiotics for healthcare-associated pneumonia" (2009). Pharmacy Practice Faculty Publications. 142. https://doi.org/10.1055/s-0028-1119813
https://collections.uhsp.edu/pharm-practice_pubs/142